CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 213 enrolled
Drug / intervention
Oleclumab +6 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03611556
NCT03611556Phase 2Completed
CompareCT.gov

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

MedImmune LLC·interventional·Posted Aug 2, 2018·Updated Oct 3, 2023

In Brief

A Phase 2 clinical trial evaluating Oleclumab, Durvalumab, and 5 other interventions for Carcinoma and Metastatic Pancreatic Adenocarcinoma. Completed, enrolled 213 participants across 27 sites in 4 countries.

Detailed Summary

The objective of this study is to evaluate the safety, tolerability, and antitumor activity of oleclumab (MEDI9447) in combination with or without durvalumab plus chemotherapy in participants with metastatic pancreatic cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Metastatic Pancreatic Adenocarcinoma
CountriesAustralia, Norway, Spain, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 2, 2018
Enrollment StartJun 21, 2018
Primary CompletionJul 22, 2022
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 7.9 years ago

Interventions

Oleclumabdrug

Participants will receive IV infusion of oleclumab as stated in arm description.

Durvalumabdrug

Participants will receive IV infusion of durvalumab as stated in arm description.

Gemcitabinedrug

Participants will receive IV infusion of gemcitabine as stated in arm description.

Nab-paclitaxeldrug

Participants will receive IV infusion of nab-paclitaxel as stated in arm description.

Oxaliplatindrug

Participants will receive IV infusion of oxaliplatin as stated in arm description.

Folinic aciddrug

Participants will receive IV infusion of folinic acid as stated in arm description.

5-FUdrug

Participants will receive IV infusion of 5-FU as stated in arm description.